NeuroTherapia, Inc.

NeuroTherapia, Inc. is a clinical stage company developing treatments for neural inflammation, initially targeting Alzheimer’s disease (AD) with an orally available small molecule, NTRX-07. In preclinical studies, NTRX-07 has been shown to bind to microglia in the brain, leading to inhibition of inflammation, improvement in long-tern potentiation, enhanced amyloid clearance and improvement in learning and memory with no evidence of psychotomimetic activity. The compound has competed Phase 1 single and multiple (7-days) ascending dose clinical studies with no evidence of dose limiting toxicity, at doses predicted to be efficacious. NTRX-07 will be advanced into a Phase II 28-day AD clinical study in 2023, in which biomarkers of neuroinflammation will be evaluated pre- and post-treatment. 

Industries

Biotechnology
Pharmaceuticals

Office Locations

Cleveland, OH